Navigation Links
Aware, Inc. Reports Second Quarter 2009 Financial Results
Date:8/1/2009

of 2009, excluding the effect of stock-based compensation, was $1.2 million, or $0.06 per diluted share. For the six months ended June 30, 2009, the company had a non-GAAP net loss, excluding the effect of stock-based compensation, of $2.9 million, or $0.13 per share.

Michael Tzannes, Aware's chief executive officer, said, "We are encouraged by the modest growth in our revenues this quarter. Our goal is to generate shareholder value by targeting growing portions of the biometrics, DSL test and home networking markets with a collection of technology, products and services."

Note: Aware's conference call will be broadcast live over the Internet today, July 30, 2009 at 5:00 p.m. Eastern Time. To listen to the call, please go to www.aware.com/ir. The conference call may also be heard by calling 719-325-2122 and referencing the confirmation number 2831084. A replay of the call will be archived on our website after the call.

About Aware

Aware is a leading technology and software supplier for the telecommunications and biometrics industries. For more than ten years, Aware has pioneered innovations at telecommunications standards-setting organizations and continues to develop and market DSL silicon intellectual property and test and diagnostics products. Its StratiPHY(tm) IP product line supports DSL standards, including ADSL2+ and VDSL2, and has been broadly licensed to leading semiconductor companies. Telecom equipment vendors and phone companies use Aware's DSL test and diagnostics modules and Dr. DSL(R) software to help provision DSL circuits globally. Aware is also a veteran of the biometrics industry, providing biometric and imaging software components used in government systems worldwide since 1992. Aware's interoperable, standard-compliant, field-proven imaging products are used in a number of applications, from border managem
'/>"/>

SOURCE Aware, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Aware, Inc. Announces Q209 Earnings Conference Call
2. Aware, Inc. Reports First Quarter 2009 Financial Results
3. Aware, Inc. Reports First Quarter 2009 Financial Results
4. Aware, Inc. Announces Final Results of Dutch Auction Tender Offer
5. Aware, Inc. Announces Q1 09 Earnings Conference Call
6. Aware, Inc. Amends and Extends Dutch Auction Tender Offer
7. Aware, Inc. Announces Preliminary Results of Dutch Auction Tender Offer
8. Aware, Inc. Amends and Extends Dutch Auction Tender Offer
9. Aware, Inc. Commences Dutch Auction Tender Offer
10. Aware, Inc. Commences Dutch Auction Tender Offer
11. Aware, Inc. Reports Fourth Quarter and 2008 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...a hormone produced in the stomach, may be used to ...arkinson,s disease, Yale School of Medicine resear...e of the Journal of Neuroscience . , Parkinson,...neurons in an area of the midbrain known as the su...production. Reduced production of dopamine in lat...
(Date:11/25/2009)...WI, NOVEMBER 25, 2009 Soil is the linchpin of the...rosphere meet. Despite that, many students see soi...ing more. Soil science educators are challenged wi...ognize the critical importance of soil in the envi...nce and earth science teachers at University of Ne...
(Date:11/24/2009)...ands of years it has been prescribed by traditiona...rom headaches and stomach pain to fever and flu. ,... University have been able to scientifically prove... otherwise known as Brazilian mint. , Testing th...ed by researcher Graciela Rocha was able to show t...
Breaking Biology News(10 mins):Hormone ghrelin can boost resistance to Parkinson's disease 2It's not just dirt! 2Got a pain? -- Have a cup of Brazilian mint 2Tyco International to Present at the Citi Industrial Manufacturing 26amp 3B Transportation Conference 60962 1Perrigo Company to Present at the Credit Suisse 18th Annual Health Care Conference 60960 1BioMed Realty Trust Receives Commitments to Expand Unsecured Line of Credit to 24665 Million 14767 1BioMed Realty Trust Receives Commitments to Expand Unsecured Line of Credit to 24665 Million 14767 2BioMed Realty Trust Receives Commitments to Expand Unsecured Line of Credit to 24665 Million 14767 3
...sonings are rare but on the riseand infants are th... of Georgia study that aims to raise awareness of ...linical professor in the UGA College of Pharmacy, ...ears of recent federal mortality data and identifi...hat corresponds to a rate of 0.26 poisonings per m...
...h & Science University researchers, along with sci... uncovering new information about the mind by stud... this research will one day provide new tools for ...the progress of treatments. The researchers, lates...c Library of Science Computational Biology . , "F...
...y of Liverpool have been awarded 1.7 million to in...ove the effectiveness of pharmaceutical drugs. , ... at sizes close to molecular level to produce part...llaborative project between the Departments of Che...techniques to develop new approaches for future dr...
Other Biology News:Study finds homicidal poisoning rising, more likely in infants and elderly 2OHSU researchers study the idling brain 2University awarded £1.7M to develop nanotechnology for use in health care 2
(Date:11/24/2009)... available in German . , Whether it,s CD pa...tags (Radio Frequency Identification) are increasi...ke it possible to label objects or goods and ident...ropriate scanner can read and process the data con...o goods under production conditions of up to 100 d...
(Date:11/24/2009)...BLENHEIM,Ontario,Nov.24/PRNewswire-FirstCall/--Dow...setsofHylandSeeds,adivisionofThompsonsLimitedofBle...xpandDowAgroSciences,currentseedsbusinessasthecomp...2010 andDowAgroSciencesHerbicideTolerantTraitTech...inthenearfuture. ,, "Thisacquisitionbringstoget...
(Date:11/24/2009)...ov.24/PRNewswire-Asia/--NODPharmaceuticalsInc.anno...edthepatentapplicationfor,itsnano-particleoraldeli...efficientapproachtoincorporatepeptidesor,proteinsi...fdrugs,otherwiseadministeredasinjections.NODtechno...cromoleculardrugssuchasinsulin,interferon,growthh...
(Date:11/24/2009)...icacyendpointhasbeenmetforpatientswithadvanced-sta...,Nov.24/PRNewswire-FirstCall/-AEternaZentarisInc.(...rmaceuticalcompanyfocusedonendocrinetherapyandonco...studywithitstargetedcytotoxicpeptideconjugate,AEZS...rentendometrialcancer.Inapersonalizedhealthcareapp...
Breaking Biology Technology:Intelligence inside metal components 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
... Nile Therapeutics, Inc.,(Nasdaq: NLTX ), today ...cer,of Nile, will present at the Rodman & Renshaw ....m. CET on Tuesday, May 20th at Le Meridian Beach,...ll provide a company,overview and update on the st...ms., The presentation will be webcast live and ca...
...lumbia and SAN DIEGO, May 13 ,Adnavance Technologi...,diagnostic tests for medical applications, announ...e, Ph.D., to its Scientific Advisory Board. Dr.,Va...spects of product,development, including design, v...for medical and diagnostic devices., Dr. Valcke c...
...Phase 2 Trials Underway, MONTVALE, N.J., May 13 ... the first patient in a 160-patient Phase 2 study,...lure. BREAK (Beginning a,Randomized Evaluation of ...r Alagebrium in Diastolic Heart Failure) is a rand...ssess the effect of six months,of oral treatment w...
Other Biology Technology:Nile Therapeutics to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference 2Adnavance Technologies Inc. Appoints Christian P. Valcke, Ph.D., to Its Scientific Advisory Board 2Adnavance Technologies Inc. Appoints Christian P. Valcke, Ph.D., to Its Scientific Advisory Board 3Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 2Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 3Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 4
Random DNA mutagenesis Service from Yorkshire Bioscience Ltd
...ated solution for scheduling, performing and docum...sting for all pipettes and liquid handling devices...pports all gravimetric calibration protocols Mee...quirements Includes setup information for balanc...
...free plasmid DNA preparations are prepared from cu...m 1mg to multi-gram scales. Small-scale (1-100mg)...tions are made according to customer specification...stomer needs, and glycerol stocks are maintained t...
...rmones which belong to the transforming growth fac... large group of extra-cellular growth factors whic...e function and tumor formation (1). Other members ...differentiation factors, AMH/MIS (Anti-Mullerian H...
Biology Products: